IDO1 and acute myeloid leukemia: Indoximod (1-methyl-D-tryptophan or D1MT) is an orally administered IDO inhibitor [78,79]; a Phase I trial (NCT02835729) is ongoing to test indoximod in combination with idarubicin and cytarabine for patients with newly diagnosed AML.